Meta Pixel

News and Announcements

Universal Biosensors (ASX:UBI) CEO Interview

  • Published July 08, 2015 4:08PM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

Universal Biosensors (ASX:UBI) is a specialist medical diagnostics company developing and manufacturing test systems for point-of-care (POC) medical professionals and home use.

UBI’s core technology is a disposable, multi-layer test strip, which uses its proprietary electrochemical sensor to rapidly and accurately measure biomarkers in the blood.

The first product developed by UBI with LifeScan (a Johnson & Johnson company) is a blood glucose measurement device and is on the market and generating revenues for UBI. The second product developed by UBI in collaboration with Siemens Healthcare has also been launched.

The global point-of-care diagnostics market is estimated to be worth nearly US$17 billion a year and growing.

Please listen to Mr Paul Wright, the CEO of Universal Biosensors.

Capital Insights
The Great Life Science Reset: Why the “Sick Care” Model is Failing

The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.

Capital Insights
Australia’s A$4 Trillion Generational Pivot

Australia’s wealth management landscape is undergoing a dramatic transformation. For decades, family offices operated quietly during the “Great Moderation”, an era characterised by low volatility, cheap capital, and global economic synchronisation. Today, that stability has given way to fiscal uncertainty, geopolitical tensions, and intensifying regulatory scrutiny. Yet amid this global turbulence, Australia has emerged as […]

Join over 45,000+ sophisticated investors

Join Now